Multiple Myeloma
Conditions
Keywords
Multiple Myeloma
Brief summary
The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.
Detailed description
The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for untreated and maladjustment to hematopoietic stem cell transplantation (HSCT) multiple myeloma to a regimen of bendamustine and prednisolone.
Interventions
DRUGSyB L-0501
SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
DRUGprednisolone
Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
Sponsors
SymBio Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
Patients are included in the study if all of the following criteria are met: Patients confirmed to have multiple myeloma (symptomatic myeloma) defined in the diagnostic criteria of the International Myeloma Working Group (IMWG). * Patients with measurable lesions * Patients with no history of treatment (no history of chemotherapy or radiotherapy) * Patients should not be considered candidates for high dose therapy/autologous stem cell transplantation due to coexistent medical conditions, advanced age, poor performance status, refusal of high dose chemotherapy, or other reasons as judged by the patient and/or physician. * Expected survival of at least 3 months * Patients aged between 20 and 79 years (at the time of provisional registration) * Performance status (P.S.) grade 0-2. P.S. 3 possible only for osteolytic lesions * Patients with adequately maintained organ function (e.g., bone marrow, heart, lungs, liver, kidneys,) * Patients from whom written consent to participate in this study has been obtained.
Exclusion criteria
Patients are excluded from participating in the study if 1 or more of the following criteria are met: * Patients with apparent infections (including viral infections) * Patients with serious complications (hepatic failure, renal failure, or diabetes with insulin administration) * Patients with complications or a medical history of serious cardiac disease (e.g., myocardial infarction, ischemic heart disease) within 2 years before preliminary registration. Patients with arrhythmia requiring treatment. * Patients with serious gastrointestinal symptoms (profound or serious nausea / vomiting or diarrhea, etc.) * Patients who were hepatitis B virus antigen (HBsAG)-positive, hepatitis C virus (HCV) antibody-positive or human immunodeficiency virus (HIV) antibody-positive * Patients with a serious bleeding tendency \[e.g., Disseminated intravascular coagulation (DIC)\] * Patients with interstitial pneumonia, pulmonary fibrosis or pulmonary emphysema requiring treatment, or such diseases in the past * Patients with apparent amyloidosis as a complication * Patients with clinical symptoms of invasion or suspected invasion of the central nervous system. * Patients with active multiple cancers * Patients who have or previously had autoimmune hemolytic anemia. * Patients administered this investigational drug in the past * Patients who received hematopoietic stem cell transplantation in the past. * Patients who received cytokines such as granulocyte colony stimulating factor (G-CSF) or erythropoietin or a blood transfusion within 1 week before the screening examination prior to preliminary registration for this study * Patients who were administered an investigational drug during a clinical study or an unapproved drug within 3 months prior to preliminary registration in this study * Patients with prior allergies to medications similar to the investigational drug (e.g., alkylating agents, or purine nucleotide analogs), mannitol or prednisolone * Patients with drug addiction, narcotic addiction or alcoholism. * Patients who were pregnant, breastfeeding women or who had a possibility to be pregnant * Patients who do not agree to contraception during the following periods. For males, during or for 6 months after completion of administration of the investigational drug. For females, during or for 3 months after completion of administration of the investigational drug * Patients whom the investigator or the sub-investigators considered to be inappropriate for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria] | Up to 36 weeks | The proportion of subjects evaluated as CR was calculated. CR (modified SWOG) requires all of the followings: 1. Decline in serum myeloma protein by ≥75% to ≤25 g/L 2. Reduction in 24 h urinary protein by ≥90% to ≤200 mg/24 h 3. No increase in skeletal destruction 4. Serum calcium within normal range 5. No blood transfusion required in the previous 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate (Based on the IMWG Criteria) | Up to 36 weeks | The proportion of subjects evaluated as response \[sCR + CR + very good partial response (VGPR) + Partial Response (PR)\] was calculated. VGPR (IMWG): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 h PR (IMWG): ≥50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥90% or to \<200mg per 24 h |
| CR Rate Based on the (Bladé) Criteria | Up to 36 weeks | The proportion of subjects evaluated as CR was calculated. CR (Bladé) requires all of the followings: 1. Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks. The presence of oligoclonal bands consistent with oligoclonal immune reconstitution does not exclude CR. 2. \<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it is not necessary to repeat the bone marrow, except in patients with non-secretory myeloma where the marrow examination must be repeated after an interval of at least 6 weeks to confirm CR. 3. No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) 4. Disappearance of soft tissue plasmacytomas |
| Response Rate (Based on the Bladé Criteria) | Up to 36 weeks | The proportion of subjects evaluated as response (CR + PR) was calculated. PR (Bladé) requires 1. or all of the others: 1. Some, but not all, of the criteria for CR are fulfilled 2. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks. 3. Reduction in 24 h urinary light chain excretion either by ≥90% or to \<200 mg, maintained for a minimum of 6 weeks. 4. For patients with non-secretory myeloma only, ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks. 5. ≥50% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination). 6. No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response). |
| Response Rate (Based on the Modified SWOG Criteria) | Up to 36 weeks | The proportion of subjects evaluated as response (CR + PR) was calculated. PR (SWOG) requires the followings: 1. Decline in myeloma protein of ≥25%-\<74% in serum myeloma protein 2. Reduction in 24h urinary myeloma protein of ≥25%-\<89% 3. No increase in skeletal destruction 4. Serum calcium within normal range |
| Progression-Free Survival (PFS) | Up to 2 years | PFS is the period from patient registration to either the date of recurrence, exacerbation, progression or death. Recurrence, exacerbation, progression were assessed from serum M-protein, urine M-protein, serum free light chain (FLC), the percentage of marrow plasma cells, disappearance of clonal plasma cells, plasma cell tumor in soft tissue, and bone lesion. |
| Time to Treatment Failure (TTF) | Up to 2 years | TTF is the period from patient registration to either the date of recurrence, exacerbation, progression, death or discontinuation of treatment. |
| Duration of Response (DOR) | Up to 2 years | DOR is the period from the date of achieving CR or PR to either the date of recurrence, exacerbation, progression or death. |
| Overall Survival (OS) | Up to 2 years | OS is the period from the date of patient registration to the date of death. |
| CR Rate [Based on the International Myeloma Working Group (IMWG) Criteria] | Up to 36 weeks | The proportion of subjects evaluated as CR \[strict CR (sCR) + CR\] was calculated. sCR (IMWG): CR as defined below plus Normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence CR (IMWG): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow |
| Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events | Up to 2 years | Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.02, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA). |
| Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values | Up to 2 years | Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to AE |
| Number of Abnormalities (Grade ≥3) in Laboratory Test Values | Up to 2 years | Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. |
| Pharmacokinetic Parameters (Cmax) | On Day 1 only | Plasma pharmacokinetics (Cmax) of unchanged bendamustine |
| Pharmacokinetic Parameters (Tmax) | On Day 1 only | Plasma pharmacokinetics (tmax) of unchanged bendamustine |
| Pharmacokinetic Parameters (AUC) | On Day 1 only | Plasma pharmacokinetics (AUC) of unchanged bendamustine |
| Pharmacokinetic Parameters (t1/2) | On Day 1 only | Plasma pharmacokinetics (t1/2) of unchanged bendamustine |
| Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event | Up to 2 years | Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.02, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA). |
Countries
Japan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SyB L-0501 + Prednisolone SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days. | 5 |
| Total | 5 |
Baseline characteristics
| Characteristic | SyB L-0501 + Prednisolone |
|---|---|
| Age Continuous | 69.0 Year STANDARD_DEVIATION 2.3 |
| Age, Customized 20-29 years | 0 Participants |
| Age, Customized 30-39 years | 0 Participants |
| Age, Customized 40-49 years | 0 Participants |
| Age, Customized 50-59 years | 0 Participants |
| Age, Customized 60-69 years | 3 Participants |
| Age, Customized 70-84 years | 2 Participants |
| Associated symptom of the primary disease No | 0 Participants |
| Associated symptom of the primary disease Yes | 5 Participants |
| Body surface area | 1.470 m2 STANDARD_DEVIATION 0.185 |
| Clinical stage [International staging system (ISS) category] Stage I | 0 Participants |
| Clinical stage [International staging system (ISS) category] Stage II | 3 Participants |
| Clinical stage [International staging system (ISS) category] Stage III | 2 Participants |
| Complications of multiple myeloma No | 0 Participants |
| Complications of multiple myeloma Yes | 5 Participants |
| Condition with symptoms of Multiple Myeloma No | 5 Participants |
| Condition with symptoms of Multiple Myeloma Yes | 0 Participants |
| Height | 151.40 cm STANDARD_DEVIATION 8.53 |
| Performance status (P.S.) 0 | 3 Participants |
| Performance status (P.S.) 1 | 0 Participants |
| Performance status (P.S.) 2 | 2 Participants |
| Performance status (P.S.) 3 | 0 Participants |
| Previous history of multiple myeloma No | 5 Participants |
| Previous history of multiple myeloma Yes | 0 Participants |
| Previous treatment of multiple myeloma No | 5 Participants |
| Previous treatment of multiple myeloma Yes | 0 Participants |
| Reason for not eligible for hematopoietic stem cell transplantation Age 66 years or older | 5 Participants |
| Reason for not eligible for hematopoietic stem cell transplantation Other | 0 Participants |
| Reason for not eligible for hematopoietic stem cell transplantation Presence of cardiopulmonary dysfunction | 0 Participants |
| Reason for not eligible for hematopoietic stem cell transplantation Renal dysfunction | 0 Participants |
| Serum β2M in clinical stage | 5.00 mg/L STANDARD_DEVIATION 1.48 |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 3 Participants |
| Weight | 52.40 kg STANDARD_DEVIATION 10.41 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 5 / 5 |
| serious Total, serious adverse events | 2 / 5 |
Outcome results
Primary
Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria]
The proportion of subjects evaluated as CR was calculated. CR (modified SWOG) requires all of the followings: 1. Decline in serum myeloma protein by ≥75% to ≤25 g/L 2. Reduction in 24 h urinary protein by ≥90% to ≤200 mg/24 h 3. No increase in skeletal destruction 4. Serum calcium within normal range 5. No blood transfusion required in the previous 3 months
Time frame: Up to 36 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB L-0501 + Prednisolone | Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria] | 40.0 Percentage of Participants |
Secondary
CR Rate Based on the (Bladé) Criteria
The proportion of subjects evaluated as CR was calculated. CR (Bladé) requires all of the followings: 1. Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks. The presence of oligoclonal bands consistent with oligoclonal immune reconstitution does not exclude CR. 2. \<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it is not necessary to repeat the bone marrow, except in patients with non-secretory myeloma where the marrow examination must be repeated after an interval of at least 6 weeks to confirm CR. 3. No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) 4. Disappearance of soft tissue plasmacytomas
Time frame: Up to 36 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB L-0501 + Prednisolone | CR Rate Based on the (Bladé) Criteria | 0.0 Percentage of participants |
Secondary
CR Rate [Based on the International Myeloma Working Group (IMWG) Criteria]
The proportion of subjects evaluated as CR \[strict CR (sCR) + CR\] was calculated. sCR (IMWG): CR as defined below plus Normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence CR (IMWG): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow
Time frame: Up to 36 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB L-0501 + Prednisolone | CR Rate [Based on the International Myeloma Working Group (IMWG) Criteria] | 0.0 Percentage of participants |
Secondary
Duration of Response (DOR)
DOR is the period from the date of achieving CR or PR to either the date of recurrence, exacerbation, progression or death.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SyB L-0501 + Prednisolone | Duration of Response (DOR) | 162.0 Days |
Secondary
Number of Abnormalities (Grade ≥3) in Laboratory Test Values
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE.
Time frame: Up to 2 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Number of Abnormalities (Grade ≥3) in Laboratory Test Values | Grade 3 abnormalities | 33 Events |
| SyB L-0501 + Prednisolone | Number of Abnormalities (Grade ≥3) in Laboratory Test Values | Grade 4 abnormalities | 39 Events |
| SyB L-0501 + Prednisolone | Number of Abnormalities (Grade ≥3) in Laboratory Test Values | Grade 5 abnormalities | 0 Events |
Secondary
Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events
Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.02, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: Up to 2 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events | Adverse events | 166 Events |
| SyB L-0501 + Prednisolone | Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events | Related adverse events | 155 Events |
| SyB L-0501 + Prednisolone | Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events | Serious adverse events | 4 Events |
| SyB L-0501 + Prednisolone | Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events | Related serious adverse events | 4 Events |
Secondary
Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to AE
Time frame: Up to 2 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values | Subjects with Grade 3 abnormality | 5 Participants |
| SyB L-0501 + Prednisolone | Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values | Subjects with Grade 4 abnormality | 5 Participants |
| SyB L-0501 + Prednisolone | Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values | Subjects with Grade 5 abnormality | 0 Participants |
Secondary
Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event
Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.02, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: Up to 2 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event | Subjects with adverse event | 5 Participants |
| SyB L-0501 + Prednisolone | Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event | Subjects with related adverse event | 5 Participants |
| SyB L-0501 + Prednisolone | Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event | Subjects with serious adverse event | 2 Participants |
| SyB L-0501 + Prednisolone | Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event | Subjects with related serious adverse event | 2 Participants |
Secondary
Overall Survival (OS)
OS is the period from the date of patient registration to the date of death.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SyB L-0501 + Prednisolone | Overall Survival (OS) | 205.0 Days |
Secondary
Pharmacokinetic Parameters (AUC)
Plasma pharmacokinetics (AUC) of unchanged bendamustine
Time frame: On Day 1 only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Pharmacokinetic Parameters (AUC) | 12315.992 ng・h/mL | Standard Deviation 7900.579 |
Secondary
Pharmacokinetic Parameters (Cmax)
Plasma pharmacokinetics (Cmax) of unchanged bendamustine
Time frame: On Day 1 only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Pharmacokinetic Parameters (Cmax) | 8795.769 ng/mL | Standard Deviation 3907.46 |
Secondary
Pharmacokinetic Parameters (t1/2)
Plasma pharmacokinetics (t1/2) of unchanged bendamustine
Time frame: On Day 1 only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Pharmacokinetic Parameters (t1/2) | 0.44 h | Standard Deviation 0.152 |
Secondary
Pharmacokinetic Parameters (Tmax)
Plasma pharmacokinetics (tmax) of unchanged bendamustine
Time frame: On Day 1 only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SyB L-0501 + Prednisolone | Pharmacokinetic Parameters (Tmax) | 1.00 h | Standard Deviation 0 |
Secondary
Progression-Free Survival (PFS)
PFS is the period from patient registration to either the date of recurrence, exacerbation, progression or death. Recurrence, exacerbation, progression were assessed from serum M-protein, urine M-protein, serum free light chain (FLC), the percentage of marrow plasma cells, disappearance of clonal plasma cells, plasma cell tumor in soft tissue, and bone lesion.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SyB L-0501 + Prednisolone | Progression-Free Survival (PFS) | 205.0 Days |
Secondary
Response Rate (Based on the Bladé Criteria)
The proportion of subjects evaluated as response (CR + PR) was calculated. PR (Bladé) requires 1. or all of the others: 1. Some, but not all, of the criteria for CR are fulfilled 2. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks. 3. Reduction in 24 h urinary light chain excretion either by ≥90% or to \<200 mg, maintained for a minimum of 6 weeks. 4. For patients with non-secretory myeloma only, ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks. 5. ≥50% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination). 6. No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response).
Time frame: Up to 36 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB L-0501 + Prednisolone | Response Rate (Based on the Bladé Criteria) | 60.0 Percentage of participants |
Secondary
Response Rate (Based on the IMWG Criteria)
The proportion of subjects evaluated as response \[sCR + CR + very good partial response (VGPR) + Partial Response (PR)\] was calculated. VGPR (IMWG): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 h PR (IMWG): ≥50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥90% or to \<200mg per 24 h
Time frame: Up to 36 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB L-0501 + Prednisolone | Response Rate (Based on the IMWG Criteria) | 60.0 Percentage of participants |
Secondary
Response Rate (Based on the Modified SWOG Criteria)
The proportion of subjects evaluated as response (CR + PR) was calculated. PR (SWOG) requires the followings: 1. Decline in myeloma protein of ≥25%-\<74% in serum myeloma protein 2. Reduction in 24h urinary myeloma protein of ≥25%-\<89% 3. No increase in skeletal destruction 4. Serum calcium within normal range
Time frame: Up to 36 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB L-0501 + Prednisolone | Response Rate (Based on the Modified SWOG Criteria) | 60.0 Percentage of participants |
Secondary
Time to Treatment Failure (TTF)
TTF is the period from patient registration to either the date of recurrence, exacerbation, progression, death or discontinuation of treatment.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SyB L-0501 + Prednisolone | Time to Treatment Failure (TTF) | 205.0 Days |